Sign In
Buy NERV
$4.68
-0.0700 (-1.47%)
At Close: Jun 03, 2026
Here’s how stress in early life leads to depression in adolescence
12:38pm, Monday, 20'th Jul 2020
While individuals taking stress are believed to develop mental health issues, a recent study has explored another aspect of taking early life stress.
Me ya sa Burtaniya ke sayar wa Saudiyya makamai? - BBC News Hausa
03:32am, Sunday, 19'th Jul 2020
Safarar makami tsakanin manyan kasashe da ke cinikinsa da Burtaniya na fuskantar bincike kan yakin Yemen, yayin da yakin basasar kasar ya shiga shekara ta biyar alkaluman farar hula da ake hallakawa n
Oppenheimer: These 2 "Strong Buy" Stocks Are Poised to Surge by Over 80%
02:02pm, Friday, 17'th Jul 2020
Another earnings season has arrived, and this time the bar is set seriously low. The upcoming reports will shed some light on the extent of the damage
Early life stress increases risk of developing depression in adulthood; Study
01:07pm, Wednesday, 15'th Jul 2020
Examining the association between eight different types of ELS and youth-onset depression, the authors found that while some types of ELS were not associated with MDD, other types of stress, including
Early life stress is associated with youth-onset depression for some types of stress | Health
07:39am, Wednesday, 15'th Jul 2020
A recent study has reported that individuals exposed to early life stress (ELS) were more likely to develop a major depressive disorder (MDD) in childhood or adolescence than individuals who had not b
3 “Perfect 10” Healthcare Stocks That Have Plenty Of Growth On Tap
12:00am, Thursday, 09'th Jul 2020
Stocks Analysis by Investing Insights covering: ChemoCentryx Inc, United Therapeutics Corporation, Axsome Therapeutics Inc. Read Investing Insights 's latest article on Investing.com
Acadia Pharmaceuticals: Evaluating The Upcoming Opportunities (NASDAQ:ACAD)
03:07am, Tuesday, 07'th Jul 2020
With the three sNDA approvals in the next three years, the share price is set to soar. Long-term investors could be generously rewarded with returns.
LivaNova announced a publication in Contemporary Clinical Trials about the RECOVER study design for VNS Therapy for treatment-resistant depression.
Minerva Neurosciences (NASDAQ:NERV) Stock Rating Reaffirmed by HC Wainwright
02:08am, Saturday, 04'th Jul 2020
Minerva Neurosciences (NASDAQ:NERV)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report released on Thursday, TipRanks reports. They presently have a $10.0
H.C. Wainwright Thinks Minerva Neurosciences' Stock is Going to Recover - Markets
10:07am, Thursday, 02'nd Jul 2020
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Minerva Neurosciences (NERV – Research
Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202)
12:00pm, Wednesday, 01'st Jul 2020
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announced today that it has exercised
Crinetics Pharmaceuticals (CRNX) Receives a Buy from H.C. Wainwright - Markets
12:13pm, Tuesday, 30'th Jun 2020
In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Crinetics Pharmaceuticals (CRNX – Research
Why Axsome Therapeutics Stock Is Sinking Today | The Motley Fool
04:45pm, Monday, 29'th Jun 2020
Some traders appear to be taking profits off the table after the stock's jump last week.
